Abstract
Objective: Next-generation sequencing (NGS)-based approaches facilitated the identification of genomic and transcriptomic alterations associated with
the development of B-cell lymphomas. Identification of these aberrancies during diagnosis may be helpful in choosing the most appropriate targeted
therapy. Follicular lymphoma and Burkitt lymphoma are B-cell non-Hodgkin lymphomas with the potential to benefit from molecular targeted therapy.
Materials and Methods: Targeted sequencing or miRNA-Seq were performed on FFPE tumor tissues of FL and pediatric BL (pBL) cases, respectively, using
the HiSeq system. Cancer- associated somatic mutations were identified in FL tumor tissue DNA samples through a computational bioinformatics pipeline.
miRNAs overexpressed in pBL cases compared with the tonsil centroblasts of non-cancer control cases were identified through differential expression
analyses. Sanger sequencing or qRT-PCR were used to cross-validate targeted NGS and miRNA-Seq results, respectively. The literature search was
performed to evaluate the therapeutic potential of these somatic mutations and upregulated miRNAs.
Results: Targeted sequencing of FL tumor tissues revealed activating mutations in genes of biological processes or oncogenic signaling pathways. Several
miRNAs were identified to be significantly overexpressed in pBL cases. The literature search revealed that targeted therapeutic approaches may be
available for the FL or pBL patients with the identified mutations or upregulated miRNAs in tumor tissues.
Conclusion: Targeted NGS may be applied during diagnosis to choose appropriate therapy for FL patients. Upregulated miRNAs provide unique
opportunities for personalized targeted therapy of pBL patients.
Keywords
Follicular Lymphoma Burkitt Lymphoma Next-generation Sequencing Molecular Targeted Therapy Precision Medicine
References
- Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5-12
Abstract
Objective: Next-generation sequencing (NGS)-based approaches facilitated the identification of genomic and transcriptomic alterations associated with
the development of B-cell lymphomas. Identification of these aberrancies during diagnosis may be helpful in choosing the most appropriate targeted
therapy. Follicular lymphoma and Burkitt lymphoma are B-cell non-Hodgkin lymphomas with the potential to benefit from molecular targeted therapy.
Materials and Methods: Targeted sequencing or miRNA-Seq were performed on FFPE tumor tissues of FL and pediatric BL (pBL) cases, respectively, using
the HiSeq system. Cancer- associated somatic mutations were identified in FL tumor tissue DNA samples through a computational bioinformatics pipeline.
miRNAs overexpressed in pBL cases compared with the tonsil centroblasts of non-cancer control cases were identified through differential expression
analyses. Sanger sequencing or qRT-PCR were used to cross-validate targeted NGS and miRNA-Seq results, respectively. The literature search was
performed to evaluate the therapeutic potential of these somatic mutations and upregulated miRNAs.
Results: Targeted sequencing of FL tumor tissues revealed activating mutations in genes of biological processes or oncogenic signaling pathways. Several
miRNAs were identified to be significantly overexpressed in pBL cases. The literature search revealed that targeted therapeutic approaches may be
available for the FL or pBL patients with the identified mutations or upregulated miRNAs in tumor tissues.
Conclusion: Targeted NGS may be applied during diagnosis to choose appropriate therapy for FL patients. Upregulated miRNAs provide unique
opportunities for personalized targeted therapy of pBL patients.
Keywords
Follicular Lymphoma Burkitt Lymphoma Next-generation Sequencing Molecular Targeted Therapy Precision Medicine
References
- Grozescu T, Popa F. Prostate cancer between prognosis and adequate/proper therapy. J Med Life. 2017;10(1):5-12
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Meeting Abstract |
| Authors | |
| Publication Date | August 9, 2022 |
| Submission Date | July 10, 2022 |
| Published in Issue | Year 2022 |